Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Ensysce Biosciences Inc ENSC

Alternate Symbol(s):  ENSCW

Healthcare Biotechnology
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ENSC)

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Accesswire 1 day ago

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Accesswire November 12, 2024

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Accesswire November 7, 2024

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

Accesswire October 8, 2024

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

Accesswire October 2, 2024

Ensysce Biosciences Receives Notice from Nasdaq

Accesswire September 27, 2024

Ensysce Biosciences Presenting at Upcoming Meetings

Accesswire September 24, 2024

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Accesswire September 19, 2024

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

Accesswire September 13, 2024
View More News ››

Opinion & Analysis (NDAQ:ENSC)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ENSC)

ENSC....almost 100 million shares have traded

Yes there was a trade to be made....my bad ! Now tell me....what will be tomorrows news.....any guesses????? Come on Audience......let...
Iseneschal - November 7, 2024

ENSC....don't even think about Chasing !!!!!

Currently trading at $0.715 on over 10 million shares...here is this a.m's NR :   Ensysce Biosciences Receives Positive...
Iseneschal - November 7, 2024

Ensysce Biosciences, Inc. (NASDAQ:ENSC): Developing Safer Pr

http://beyondspx.com/2024/08/01/ensysce-biosciences-inc-nasdaqensc-developing-safer-prescription-drugs-through-innovative-abuse-and...
MikeTester - August 2, 2024

Ensysce Biosciences Selected to Present at American Associat

JUST IN: $ENSC Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference~ PF614-MPAR recognized...
whytestocks - February 6, 2024

(NASDAQ: ENSC) Higher on Positive End of Phase 2 FDA Meeting

Breaking News: $ENSC (NASDAQ: ENSC) Higher on Positive End of Phase 2 FDA Meeting2024-01-31 09:03:48 ET DENVER, Colo., Jan. 31, 2023...
whytestocks - January 31, 2024

Ensysce Biosciences Announces FDA Breakthrough Therapy Desig

Just In: $ENSC Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR~ FDA acknowledges significant...
whytestocks - January 23, 2024
View more Bullboard ››

SKRR Exploration Inc.

SKRR Exploration Inc.

SKRR Exploration Inc. is a Canada-based precious and base metal explorer with properties in Saskatchewan. The Company's ...
View More »